Medical devices, healthcare technology and the business of care
PMA approval · P240014

MAGiC Ablation Catheter

Stereotaxis, Inc. · Decision date Jan 5, 2026

FDA DECISIONP240014

What did the FDA approve?

FDA records P240014 as an original PMA application. The recorded decision is approval, dated Jan 5, 2026.

FDA approval order statement

approval for the MAGiC Ablation Catheter. This device is indicated for: The MAGiC Magnetic Interventional Ablation Catheter is indicated for cardiac electrophysiological mapping, delivering diagnostic pacing stimuli, and for the creation of endocardial lesions to treat supraventricular tachycardia (e.g., macroreentrant atrial tachycardia, focal atrial tachycardia, atrioventricular nodal reentrant tachycardia, and atrioventricular reentrant tachycardia) in patients with congenital heart disease in whom vascular or target chamber access by conventional manual catheter navigation is limited due to underlying anatomic abnormalities and/or previous surgical interventions.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Jan 5, 2026

FDA source record

Regulatory record facts

Identifier
P240014
Regulatory pathway
Premarket approval application
Product code
LPB
Decision code
APPR
Decision date
Jan 5, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Cardiac ablation percutaneous catheter.

Product code
LPB
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P240014 received

    Application receipt date recorded by FDA.

  2. P240014 · FDA decision

    APPR

  3. P240014/S001 · Related supplement

    MAGiC Ablation Catheter

Timeline entries are records held by MedtechLedger for P240014. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240014

Product / regulatory recordCompanyPathwayDecision dateSource
Stereotaxis, Inc.PMA supplementJul 31, 2026FDA

Explore the linked device profile

Other records with product code LPB

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Stereotaxis, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
710 Tucker Blvd., Suite 110, Saint Louis, MO, 63101

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records